摘要
选择性5-羟色胺再摄取抑制剂(SSRIs)常见于女性性功能障碍服用。女性性功能的复杂性是通过调节神经心理生理因素、人际关系问题、精神疾病和生理障碍等相互作用因素反映出来的。SSRIS引起的FSD的发生率很难估计,因为SSRIS的潜在混淆效应、多药、婚姻效应、社会文化因素以及大多数研究中的设计和评估问题。FSD诱导的SSRIs的确切机制尚不清楚,虽然SSRIs如一氧化氮(NO)、去甲肾上腺素(Noradrenergic)和多巴胺(DA)等可能调节其他神经递质系统,但目前有关SSRIs引起FSD的潜在机制的证据还不清楚,包括性欲低(性欲低)、觉醒困难(缺乏润滑)和性欲不足。FSD与SSRI的特异性关联尚未被证实。这种关系是剂量依赖性的,在5-羟色胺和多巴胺再摄取的机制、垂体催乳素释放的诱导、抗胆碱能副作用、抑制NO合成和情感记忆回路加密性体验等方面存在差异。治疗SSRI所致的FSD有多种干预策略,包括耐受性、滴定剂量、替代另一种抗抑郁药物和心理治疗。需要更好地理解SSRI诱导的FSD,以获得更好的治疗效果。
关键词: 抗抑郁药,女性性功能障碍,精神障碍,5-羟色胺选择性再摄取抑制剂,5-羟色胺受体,多巴胺再摄取。
图形摘要
Current Drug Targets
Title:Serotonin Selective Reuptake Inhibitors (SSRIs) and Female Sexual Dysfunction (FSD): Hypothesis on its Association and Options of Treatment
Volume: 19 Issue: 12
关键词: 抗抑郁药,女性性功能障碍,精神障碍,5-羟色胺选择性再摄取抑制剂,5-羟色胺受体,多巴胺再摄取。
摘要: Sexual dysfunctions are commonly seen in women on selective serotonin reuptake inhibitors (SSRIs). The complexities of female sexual functioning are reflected through modulation of inter- playing factors like the neuropsychophysiological factors, inter-personal and relationship issue, psychiatric co-morbidities and physical disorder. The incidence of SSRIs-induced FSD is difficult to estimate because of the potential confounding effects of SSRIs, presence of polypharmacy, marital effect, socio-cultural factors and due to the design and assessment problems in majority of the studies. The exact mechanism of FSD-induced SSRIs is unknown. It has been postulated that although SSRIs may modulate other neurotransmitter system such as nitric oxide (NO), noradrenergic and dopamine in inducing FSD. In the present review, we highlight current evidence regarding potential mechanism of SSRIs in causing FSD, which include low sexual desire (low libido), arousal difficulties (lack of lubrication), and anorgasmia. The specific association of FSD to SSRI use, has not been ellucidated. The relationship is dose-dependent, and may vary among the groups with respect to mechanism of serotonin and dopamine reuptake, induction of release of prolactin from the pituitary gland, anticholinergic side-effects, inhibition of NO synthesis and emotional-memory circuit encryption for sexual experiences. Various interventional strategies exist regarding the treatment of SSRI-induced FSD and this includes tolerance, titration dosage, substitution to another antidepressant drug and psychotherapy. There is a need of better understanding of SSRIs-induced FSD for better treatment outcome.
Export Options
About this article
Cite this article as:
Serotonin Selective Reuptake Inhibitors (SSRIs) and Female Sexual Dysfunction (FSD): Hypothesis on its Association and Options of Treatment, Current Drug Targets 2018; 19 (12) . https://dx.doi.org/10.2174/1389450117666161227142947
DOI https://dx.doi.org/10.2174/1389450117666161227142947 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Brain Injury Associated with Widely Abused Amphetamines: Neuroinflammation, Neurogenesis and Blood-Brain Barrier
Current Drug Abuse Reviews Atypical Antipsychotic Drugs During Pregnancy. Their Effects on the Mother and Offspring
Current Women`s Health Reviews In memory of Prof. Stephen Drake Skaper
CNS & Neurological Disorders - Drug Targets Excessive Indoor Tanning as a Behavioral Addiction: A Literature Review
Current Pharmaceutical Design Synthesis and Evaluation of Novel Diazaspiro Hydantoins as Potential Anticonvulsants
Central Nervous System Agents in Medicinal Chemistry Testosterone and Cognition in Normal Aging and Alzheimers Disease: An Update
Current Alzheimer Research Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry Validated Microemulsion Liquid Chromatography-Fluorescence Method for the Quantification of Duloxetine and its Two Main Metabolites in Plasma: Application to Clinical Pharmacokinetic Studies
Current Pharmaceutical Analysis Editorial (Thematic Issue: Translational Investigations for Chronic Pain)
Current Pharmaceutical Design Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs
Current Pharmaceutical Design Recent Advances in Nutrition for the Treatment of Depressive Disorder
Current Pharmaceutical Design The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice
CNS & Neurological Disorders - Drug Targets Global Account of Barriers and Facilitators of Physical Activity Among Patients with Diabetes Mellitus: A Narrative Review of the Literature
Current Diabetes Reviews Computational Approaches to Screen Candidate Ligands with Anti- Parkinson’s Activity Using R Programming
Current Topics in Medicinal Chemistry 3-(1H-Pyrrol-2-yl)-2-oxazolidinones as Novel Monoamine Oxidase Type A Inhibitors
Medicinal Chemistry Intrahippocampal Transplantation of Undifferentiated Human Chorionic- Derived Mesenchymal Stem Cells Does Not Improve Learning and Memory in the Rat Model of Sporadic Alzheimer Disease
Current Stem Cell Research & Therapy Potential Implications of Research on Genetic or Heritable Contributions to Pedophilia for the Objectives of Criminal Law
Recent Advances in DNA & Gene Sequences (Discontinued) Evidence of Nestin-Positive Cells in the Human Cutaneus Meissner and Pacinian Corpuscles
CNS & Neurological Disorders - Drug Targets The Role of P-glycoprotein in Cerebral Amyloid Angiopathy; Implications for the Early Pathogenesis of Alzheimers Disease
Current Alzheimer Research Editorial: Are We in Need for Novel Therapeutics in Anxiety Disorders? (Thematic Issue: Non-Antidepressant Long Term Treatment of Anxiety Disorders)
Current Clinical Pharmacology